Individualizing First-Line Checkpoint Inhibitor Selection in an Older Comorbid Patient

Dr Whitman describes what stands out clinically about the 79-year-old patient, beginning with the interaction between advanced age, accumulated chronic disease, and the clinical impression formed at the bedside. The faculty discuss how frailty and comorbidity burden influence which checkpoint inhibitor they select when efficacy across agents appears comparable. Dr Whitman explains why the favorable immune-related toxicity profile led him toward cosibelimab in a patient of this complexity, and Dr In confirms this reflects his own recent practice, noting he has made the same recommendation for patients over 80 years of age and several patients in their 90s. Dr In briefly references the accumulating body of data on the agent, including updated analyses presented at recent meetings and published follow-up, which have continued to show low rates of immune-related toxicity with longer observation. The segment illustrates individualized first-line selection in an older, comorbid population.